Moreover, high FSCN1 expression was strongly associated with poor clinical outcomes and could be used as a prognostic and predictive biomarker in different cancer types, including nonsmall cell lung cancer 19, urinary bladder urothelial carcinoma 20 and breast cancer 21, 22. Here, FSCN1 is linked to breast carcinoma.